These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36423044)

  • 21. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol.
    Marshall HS; Andraweera PH; Wang B; McMillan M; Koehler AP; Lally N; Almond S; Denehy E; A'Houre M; Giles LC; Flood L
    Hum Vaccin Immunother; 2021 May; 17(5):1450-1454. PubMed ID: 33428528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meningococcal B vaccine induces cross-protection against gonorrhea.
    Azze RFO
    Clin Exp Vaccine Res; 2019 Jul; 8(2):110-115. PubMed ID: 31406692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction by genetic MATS of 4CMenB vaccine strain coverage of invasive meningococcal serogroup B isolates circulating in Taiwan between 2003 and 2020.
    Muzzi A; Lu M-C; Mori E; Biolchi A; Fu T; Serino L
    mSphere; 2024 Jun; 9(6):e0022024. PubMed ID: 38752729
    [No Abstract]   [Full Text] [Related]  

  • 28. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Tzeng YL; Sannigrahi S; Borrow R; Stephens DS
    Front Immunol; 2024; 15():1350344. PubMed ID: 38440731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neisseria gonorrhoeae vaccine development: hope on the horizon?
    Edwards JL; Jennings MP; Seib KL
    Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study.
    Raccagni AR; Galli L; Spagnuolo V; Bruzzesi E; Muccini C; Bossolasco S; Ranzenigo M; Gianotti N; Lolatto R; Castagna A; Nozza S
    Sex Transm Dis; 2023 May; 50(5):247-251. PubMed ID: 36728240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK.
    Ladhani SN; White PJ; Campbell H; Mandal S; Borrow R; Andrews N; Bhopal S; Saunders J; Mohammed H; Drisdale-Gordon L; Callan E; Sinka K; Folkard K; Fifer H; Ramsay ME
    Lancet Infect Dis; 2024 Sep; 24(9):e576-e583. PubMed ID: 38521080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-protection induced by VA-MENGOC-BC® vaccine.
    Ochoa-Azze RF
    Hum Vaccin Immunother; 2018 May; 14(5):1064-1068. PubMed ID: 29420119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neisseria proteomics for antigen discovery and vaccine development.
    Christodoulides M
    Expert Rev Proteomics; 2014 Oct; 11(5):573-91. PubMed ID: 25017717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promising developments in gonococcal vaccines.
    Waltmann A; Chen JS; Duncan JA
    Curr Opin Infect Dis; 2024 Feb; 37(1):63-69. PubMed ID: 38050729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae.
    Hadad R; Jacobsson S; Pizza M; Rappuoli R; Fredlund H; Olcén P; Unemo M
    APMIS; 2012 Sep; 120(9):750-60. PubMed ID: 22882265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.
    Terranova L; Principi N; Bianchini S; Di Pietro G; Umbrello G; Madini B; Esposito S
    Hum Vaccin Immunother; 2018 May; 14(5):1070-1074. PubMed ID: 29584565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses to
    Belcher T; Rollier CS; Dold C; Ross JDC; MacLennan CA
    Front Immunol; 2023; 14():1248613. PubMed ID: 37662926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.